Our Story
Gracell Biotechnologies is a clinical-stage biotech company with mission to solve CAR-T industry hurdles, including :
Lengthy and ineffecient manufacturing process
Overnight production (FasTCAR™)
High cost of goods
Lower COGs (FasTCAR™, TruUCAR™)
Lack of off-the-shelf products
Ineffectiveness against solid tumors
Enhanced CAR™
Being committed to research and development, Gracell is bringing affordable, but highly cost-effective adoptive immunotherapy to patients.
  • 08.2019
    GC012F (redirected to target BCMA and Ag X) enrolled 1st MM patient
  • 06.2019
    Interim clinical readout of GC007F announced on the CAR-TCR Summit Asia
  • 02.2019
    Completion of B round of financing $85M USD
  • 12.2018
    First FasT CAR program GC007F enrolled 1st B-ALL patient
  • 04.2018
    GMP facility settled in Suzhou Biobay Industrial Park
  • 08.2017
    Completion of A round of financing $10M USD
  • 05.2017
    Gracell biotechnologies was registered and open to operation